How to Get Zepbound in New Hampshire

What Is Zepbound and Why Does It Work?

Zepbound is the brand name for tirzepatide, a dual GIP/GLP-1 receptor agonist that Eli Lilly developed for chronic weight management. The FDA approved Zepbound in November 2023 for adults with obesity (BMI ≥30) or overweight (BMI ≥27) who have at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia.

How Tirzepatide Produces Weight Loss

Tirzepatide activates both GIP and GLP-1 receptors, a mechanism that separates it from single-incretin drugs like semaglutide. By targeting two incretin pathways simultaneously, tirzepatide slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves insulin sensitivity. The SURMOUNT-1 trial (N=2,539) demonstrated that participants receiving 15 mg tirzepatide lost 22.5% of body weight at 72 weeks compared with 2.4% in the placebo group [1]. That result exceeds outcomes reported in the STEP-1 semaglutide trial, which showed 14.9% weight loss at 68 weeks [2].

Clinical Trial Evidence Beyond SURMOUNT-1

SURMOUNT-2 enrolled adults with both obesity and type 2 diabetes. Participants on 15 mg tirzepatide achieved 14.7% mean body weight reduction at 72 weeks versus 3.2% with placebo [3]. A pooled safety analysis published in The Lancet Diabetes & Endocrinology confirmed that GI side effects (nausea, diarrhea, constipation) were the most common adverse events, occurring in roughly 25 to 33% of participants, and were generally mild to moderate [4].

These trials form the clinical basis that New Hampshire prescribers use when evaluating whether a patient qualifies for Zepbound.

Who Can Prescribe Zepbound in New Hampshire?

New Hampshire allows physicians (MDs and DOs), nurse practitioners (APRNs), and physician assistants (PAs) to prescribe Zepbound. APRNs in New Hampshire have full practice authority under RSA 326-B, meaning they can prescribe controlled and non-controlled medications independently without a collaborative agreement.

In-Person vs. Telehealth Prescribers

You can see a provider face-to-face at an endocrinology, obesity medicine, or primary care clinic. Alternatively, New Hampshire permits telehealth prescribing for non-controlled substances, and Zepbound is not a controlled substance. The New Hampshire Board of Medicine requires that telehealth prescribers hold an active New Hampshire medical license or participate in an interstate compact. The Ryan Haight Act does not restrict telehealth prescribing of Zepbound because tirzepatide is not a DEA-scheduled drug.

Choosing a Telehealth Provider

When selecting a telehealth platform, verify three things. First, confirm the prescriber holds a valid New Hampshire license. Second, check whether the platform partners with pharmacies that ship to New Hampshire addresses. Third, ask whether the platform handles prior authorization on your behalf, since this step can delay treatment by one to three weeks if you file it yourself.

What Labs Are Needed Before Starting Zepbound?

Most prescribers in New Hampshire require baseline labs before writing a Zepbound prescription. These labs serve two purposes: confirming medical eligibility and establishing safety baselines.

Standard Pre-Prescribing Lab Panel

A typical pre-Zepbound workup includes a comprehensive metabolic panel (CMP) to assess kidney and liver function, HbA1c to screen for diabetes or prediabetes, a fasting lipid panel, and thyroid-stimulating hormone (TSH). The Endocrine Society's 2023 guidelines on pharmacotherapy for obesity recommend screening for secondary causes of obesity (hypothyroidism, Cushing syndrome) before initiating any anti-obesity medication [5].

Why Thyroid Screening Matters

Tirzepatide carries a boxed warning about medullary thyroid carcinoma (MTC) risk based on rodent studies. The FDA prescribing information states that Zepbound is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]. Your prescriber will check your thyroid history and may order a calcitonin level if clinical suspicion exists.

Additional Screening for Comorbidities

Patients with a history of pancreatitis should have lipase checked. Those with retinopathy need an ophthalmologic evaluation, as rapid glycemic improvement with GLP-1 receptor agonists has been associated with worsening of pre-existing diabetic retinopathy in some studies [7]. A gallbladder history review is also standard since GLP-1-class medications are associated with increased cholelithiasis risk [8].

Insurance Coverage and Prior Authorization in New Hampshire

The cost field for Zepbound in New Hampshire varies dramatically by payer type. Branded Zepbound carries a list price of roughly $1,060 per month without insurance.

Commercial Insurance

Most large commercial insurers (Anthem, Cigna, Aetna, UnitedHealthcare) cover Zepbound with prior authorization for members who meet FDA label criteria. The American Association of Clinical Endocrinology (AACE) consensus statement recommends that insurers cover anti-obesity medications as part of comprehensive obesity care [9]. Prior authorization typically requires documentation of BMI ≥30 (or ≥27 with a comorbidity), at least one failed lifestyle intervention (documented dietary counseling or exercise program), and baseline lab results confirming no contraindications.

New Hampshire Medicaid

New Hampshire Medicaid does not cover Zepbound for chronic weight management as of the most recent formulary update. This gap is consistent with CMS policy, which allows but does not mandate state Medicaid programs to cover anti-obesity medications. Patients on Medicaid may consider 503A compounded tirzepatide as a lower-cost alternative (discussed below) or the Eli Lilly savings program for commercially insured patients.

Medicare Part D

Medicare Part D historically excluded anti-obesity medications. However, the Treat and Reduce Obesity Act provisions and recent CMS guidance have expanded coverage for GLP-1 agonists in Medicare beneficiaries with established type 2 diabetes. If you carry a Part D plan in New Hampshire and have a diabetes diagnosis, your plan may cover Zepbound under the diabetes indication (Mounjaro) rather than the obesity indication (Zepbound) [10].

What Documentation Does Prior Authorization Require?

A complete prior authorization packet for Zepbound in New Hampshire typically includes: a letter of medical necessity from the prescriber, documented BMI measurements from at least two visits, lab results (HbA1c, CMP, lipid panel, TSH), a record of previous weight management attempts lasting at least three to six months, and documentation of qualifying comorbidities. Some insurers also require evidence that the patient has not responded to or is intolerant of other anti-obesity medications such as phentermine/topiramate or naltrexone/bupropion.

Pharmacy Options in New Hampshire

Once your prescription is written and approved (if prior authorization applies), you need a pharmacy that stocks or can order Zepbound.

Retail Pharmacies

Major chains (CVS, Walgreens, Rite Aid) in New Hampshire can dispense branded Zepbound. Supply fluctuations have been common since launch due to high demand. The FDA's drug shortage database has intermittently listed tirzepatide dose strengths as limited in distribution [11]. Calling ahead to confirm stock is recommended.

503A Compounding Pharmacies

New Hampshire licenses 503A compounding pharmacies under the New Hampshire Board of Pharmacy. These pharmacies may compound tirzepatide when there is a valid patient-specific prescription and when commercial supply is limited. The FDA's guidance on 503A compounding requires that 503A pharmacies compound in response to an individual prescription, not for general distribution [12]. Compounded tirzepatide typically costs $300 to $550 per month, depending on dose and pharmacy.

Mail-Order and Specialty Pharmacies

Many telehealth platforms partner with specialty mail-order pharmacies that ship directly to New Hampshire addresses. The NABP (National Association of Boards of Pharmacy) accredits verified pharmacy distributors. Confirm that any mail-order pharmacy holds appropriate state and federal licenses before purchasing.

Step-by-Step: Getting Zepbound in New Hampshire

This section walks through the process from first appointment to first injection.

Step 1: Schedule a Qualifying Visit

Book an appointment with a licensed prescriber (MD, DO, APRN, or PA) in New Hampshire, either in person or via telehealth. Bring your weight history, any previous diet or exercise documentation, and a list of current medications.

Step 2: Complete Baseline Labs

Your provider will order a CMP, HbA1c, lipid panel, and TSH at minimum. Labs can be drawn at Quest Diagnostics, Labcorp, or hospital-affiliated labs throughout New Hampshire. Most results return within 24 to 72 hours.

Step 3: Receive Your Prescription

If you meet FDA label criteria (BMI ≥30, or BMI ≥27 with a weight-related comorbidity), your provider will write a Zepbound prescription starting at 2.5 mg weekly. The FDA label specifies a dose-escalation schedule: 2.5 mg for weeks 1 through 4, then 5 mg for weeks 5 through 8, with further increases every 4 weeks to a maximum of 15 mg [6].

Step 4: File Prior Authorization (If Required)

Your prescriber or telehealth platform submits prior authorization to your insurer. Average turnaround in New Hampshire is 5 to 10 business days. Some insurers offer expedited 48-hour review for urgent medical cases.

Step 5: Fill at Your Chosen Pharmacy

Once approved, your prescription routes to a retail, specialty, or compounding pharmacy. Branded Zepbound ships as a prefilled single-dose pen. Compounded tirzepatide may ship as a multi-dose vial requiring self-injection with insulin syringes.

Step 6: Begin Treatment and Follow Up

Inject once weekly, rotating injection sites among the abdomen, thigh, and upper arm. Your provider should schedule a follow-up within 4 to 8 weeks to assess tolerability and adjust dosing. The AGA clinical practice guideline on pharmacotherapy for obesity recommends ongoing monitoring of weight, metabolic markers, and gastrointestinal symptoms at each dose escalation [13].

Transferring a Zepbound Prescription to New Hampshire

If you already have a Zepbound prescription from another state, transferring it to a New Hampshire pharmacy is straightforward. Under New Hampshire Board of Pharmacy rules, pharmacists can accept prescription transfers for non-controlled medications electronically or by phone. Your current pharmacy contacts the receiving New Hampshire pharmacy, verifies remaining refills, and completes the transfer. The process typically takes one to two business days. If your prescriber is not licensed in New Hampshire, you will need a new prescription from an NH-licensed provider.

How Long Until You Receive Zepbound in New Hampshire?

Timeline estimates break down into three phases. The clinical visit and labs take 3 to 7 days. Prior authorization, if required, adds 5 to 10 business days. Pharmacy processing and shipping add another 2 to 5 business days. Total: roughly 10 to 22 business days from first appointment to first injection. Patients paying out of pocket or using compounding pharmacies often skip the prior authorization phase entirely, shortening the timeline to 5 to 12 days.

Safety Monitoring and Ongoing Care

Once on Zepbound, periodic monitoring ensures both efficacy and safety.

Recommended Follow-Up Labs

Repeat HbA1c, CMP, and lipid panel at 3 months, then every 6 months. The AACE/ACE comprehensive clinical practice guidelines recommend monitoring renal function in patients with pre-existing CKD, as dehydration from GI side effects could worsen kidney function [14].

Managing Common Side Effects

Nausea affects roughly 25 to 30% of patients, based on SURMOUNT-1 data [1]. Eating smaller meals, staying hydrated, and avoiding high-fat foods reduce symptom severity. If nausea persists beyond the first 4 to 6 weeks, your prescriber may slow the dose-escalation schedule rather than discontinuing treatment.

When to Contact Your Provider Immediately

Severe abdominal pain (possible pancreatitis), symptoms of gallbladder disease (right upper quadrant pain, jaundice), or signs of allergic reaction (angioedema, difficulty breathing) require immediate medical evaluation. The FDA adverse event reporting system (FAERS) collects post-market safety data on tirzepatide; patients can report adverse events through MedWatch [15].

Cost-Saving Strategies for New Hampshire Residents

Branded Zepbound at list price is expensive. Several strategies can reduce out-of-pocket costs.

Eli Lilly offers a savings card for commercially insured patients that may reduce copays to as little as $25 per month for eligible individuals. Patients without commercial insurance can explore the Lilly Cares patient assistance program for potential free or reduced-cost medication [16]. 503A compounded tirzepatide, as noted above, ranges from $300 to $550 per month. GoodRx and similar discount platforms may offer negotiated rates at participating New Hampshire pharmacies, though discounts on branded Zepbound remain limited due to manufacturer pricing controls.